


# Previous ABCD GLP1 RA Nationwide Audits

- Combined trials v real world

	Clinical trials combined	Real clinical use in UK (ABCD audit)
	Baseline HbA <sub>1c</sub> (%)	
Exenatide	8.37	9.47
Liraglutide	8.5	9.40
	Baseline BMI (kg/m <sup>2</sup> )	
Exenatide	32.72	39.8
Liraglutide	31	39.0

# SUSTAIN trials – baseline HbA<sub>1c</sub>

ESTIMATED CHANGE IN HbA<sub>1c</sub>



\*p<0.0001 vs comparator.

Exenatide OW, exenatide once weekly; IGLar, insulin glargine.

1. Sorli et al. *Lancet Diabetes Endocrinol* 2017;5:251–260; 2. Ahren et al. *Lancet Diabetes Endocrinol* 2017;5:341–354; 3. Ahmann et al. *Diabetes Care* 2018;41:258–266; 4. Arora et al. *Lancet Diabetes Endocrinol* 2017;5:355–366; 5. Rodbard et al. *The Journal of Clinical Endocrinology and Metabolism* 2018, 103(6):2291–2301; 6. Pratley et al. *Lancet Diabetes Endocrinol* 2018; [6\(4\)](#):275–286